Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Profit After Tax: 2014-2024

Historic Profit After Tax for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to -$77.4 million.

  • Cartesian Therapeutics' Profit After Tax fell 48.46% to -$35.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.0 million, marking a year-over-year increase of 80.40%. This contributed to the annual value of -$77.4 million for FY2024, which is 64.76% up from last year.
  • Latest data reveals that Cartesian Therapeutics reported Profit After Tax of -$77.4 million as of FY2024, which was up 64.76% from -$219.7 million recorded in FY2023.
  • In the past 5 years, Cartesian Therapeutics' Profit After Tax ranged from a high of $35.4 million in FY2022 and a low of -$219.7 million during FY2023.
  • Its 3-year average for Profit After Tax is -$87.3 million, with a median of -$77.4 million in 2024.
  • Per our database at Business Quant, Cartesian Therapeutics' Profit After Tax surged by 237.73% in 2022 and then plummeted by 721.02% in 2023.
  • Yearly analysis of 5 years shows Cartesian Therapeutics' Profit After Tax stood at -$68.9 million in 2020, then soared by 62.71% to -$25.7 million in 2021, then skyrocketed by 237.73% to $35.4 million in 2022, then slumped by 721.02% to -$219.7 million in 2023, then spiked by 64.76% to -$77.4 million in 2024.